ABG Sundal Collier Sponsored - C-RAD AB (CRAD B) C-RAD AB - Resilient despite weaker end markets

Almost there...

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

First Name*

Last Name*

Country*

Email*

Password* ( 6 or more alphabetic and numerical characters )

Get financial insights straight to your inbox

YES

I have read and accept ResearchPool Terms & Conditions, and Privacy Policy, including our Cookie Use Policy

Already on ResearchPool? Login Now

Report

ABG Sundal Collier Sponsored

Erik Cassel

C-RAD AB - Resilient despite weaker end markets

Exceptional Q3 sales and EBIT, but orders came in weak We cut ’24e EBIT by 3% on end-market weakness Fair value range of SEK 45-95/share

30/10/2022 1 EN

Underlying

C-RAD AB

C-Rad is engaged in development and sales of innovative systems with applications in advanced radiation therapy for the treatment of cancer. The systems can be used to localize the tumor before treatment and to position the patient and monitor treatment by recording information such as patient movements during radiation treatment. The aim is to increase the accuracy and efficiency of radiotherapy as well as to minimize radiation damage to the patient's healthy tissue.

See profile

SE0002016352 Nasdaq Nordic Stockholm Sweden

Provider

ABG Sundal Collier Sponsored

ABG Sundal Collier is the independent, Nordic investment banking powerhouse, developed over 30 years, founded on a hard working partnership culture and the ability to attract top talent.

Our strategy is to be an advisor and an intermediary, and the core product offering comprise corporate advisory services, corporate financing services and investor research and brokerage services.

Our corporate advisory team offers access to a broad financial and industrial network and unparalleled transaction experience. We provide financing to corporates through our superior Nordic and international distribution platform, and we are optimally structured for naturally matching trading flows, delivering best execution for clients.

The group employ approx. 250 staff working from the Nordic offices in Norway, Sweden and Denmark and in the offices in the key international markets US, UK and Germany.

See profile

Analysts

Erik Cassel

Other Reports on these Companies

SmartInsider

C-Rad AB: 1 director

A director at C-Rad AB bought 8,000 shares at 32.000SEK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board memb...

Free Trial

March 10, 2023 March 10, 2023 1 EN

ABG Sundal Collier

Sector Fast Comment - Hospital data update

Better hospital margins in September Weaker procedure volume momentum into Q4 Small positive for capex exposure

November 9, 2022 November 9, 2022 1 EN

Approaching the split with a solid Q1e

12% organic growth on tough P&S comps while we expect an acceleration from Q2. Trading at ~6x '24e EV/EBITDA, 15% below peers avg.

1h / 32m 1h / 32m 1 EN

ABGSC Retail Research ... (+3)

ABGSC Retail Research
Benjamin Wahlstedt
Nikola Kalanoski

Doing all the right things

'24e-'26e EBITA down 7-1% primarily due to changes in capitalisation policy. '24e-'25e lease adj. FCFE yield excl. earn-outs of ~8%.

1h / 44m 1h / 44m 1 EN

ABGSC IT Research ... (+2)

ABGSC IT Research
Nikola Kalanoski

Taking action amid tough conditions

We cut '24e and '25e EBITDA by 17% and 8%. Refocusing of Aurdel to improve margin stability. '25e EV/EBIT of ~11x.

1h / 56m 1h / 56m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

C-RAD AB - Resilient despite weaker end markets

C-Rad AB: 1 director

Sector Fast Comment - Hospital data update

Approaching the split with a solid Q1e

Doing all the right things

Taking action amid tough conditions

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe